Short courses of intravenous clodronate in the treatment of Paget's disease of bone: a long-term follow-up trial.
The effect of short-term treatment with intravenous clodronate (300 mg daily for 10 days) was assessed in 12 patients with active Paget's disease of bone. The treatment was found to be associated with a marked reduction in serum alkaline phosphatase levels, from 330 U/l +/- 247 (S.D.) at baseline to 225 +/- 86 on day 11. These levels decreased further during the subsequent 2 months, to stabilize thereafter within the normal range (30-100 U/l)during the entire 1-year follow-up period. No changes were observed in serum calcium and phosphorus levels, whereas serum parathyroid hormone increased significantly on day 11. It is concluded that short-term i.v. treatment with clodronate provides an effective alternative to oral treatment and achieves complete remission of Paget's disease for at least 1 year.
Broggini
M
M
Department of Medicine, Filippo Del Ponte Hospital, Varese, Italy.
Baratelli
E
E
Cappelli
A
A
Marconi
A
A
Ghiringhelli
D
D
Salzillo
A
A
D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D002118:Calcium / Q000097:blood; D004002:Clodronic Acid / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood
D010281:Parathyroid Hormone; D004002:Clodronic Acid; D010758:Phosphorus; D000469:Alkaline Phosphatase; D002118:Calcium